XTL Biopharmaceuticals Ltd. (XTLB) is a public biopharmaceutical company dedicated to the development and commercialization of innovative drugs for the treatment of autoimmune diseases and cancer. The company was founded in 1993, and it is listed on both the NASDAQ Capital Market and the Tel Aviv Stock Exchange.
XTL Biopharmaceuticals' main research and development focus is on major, high-potential market opportunities in the autoimmune diseases and cancer therapeutics areas, with a particular interest in orphan drug indications. Its lead drug candidate, hCDR1, is for the treatment of systemic lupus erythematosus ("SLE") and Sjogren's syndrome ("SjS"). The company expects to initiate a phase 2 clinical trial for hCDR1 in SLE patients, subject to receiving regulatory approval.
XTL Biopharmaceuticals is headquartered in Israel and operates through its wholly-owned subsidiaries; XTL Development, Inc. in the United States and KM Medical Ltd. in Israel. The company’s strategic approach is to engage with pharmaceutical and biotech companies in co-development or licensing agreements, therefore leveraging its research and development capabilities with the objective of minimizing risks and sharing costs.
The company has consistently demonstrated a commitment to the development of novel therapies to meet unmet medical needs, and it has demonstrated robust expertise in the identification, in-licensing, and clinical development of promising drug candidates, which it typically acquires from renowned research institutions and biotech companies globally.
Backed by a team of seasoned industry professionals, XTL Biopharmaceuticals' management team exhibits in-depth knowledge of drug discovery, clinical development, regulatory affairs, and biotech business development. The team focuses on advancing their products through regulatory pathways to commercialization while seeking strategic partnerships to support this process.
XTL Biopharmaceuticals' approach and dedication to addressing the treatment of autoimmune diseases and cancer differentiate it in the biotech industry. The company's commitment to innovation, meticulous research, and precise execution is evident in their efforts to develop cutting-edge therapies for patients. However, where XTL Biopharmaceuticals truly excels is in its balancing act between bold scientific exploration and the pragmatic considerations of developing, testing, and commercializing drugs, all while keeping the patients' well-being and improved quality of life at the forefront of their goals.